Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 46

Results For "NIV"

1031 News Found

Dr Mandaviya addresses WHO’s public launch event of GIDH
News | February 22, 2024

Dr Mandaviya addresses WHO’s public launch event of GIDH

Global Initiative on Digital Health (GIDH) was launched by the WHO and the Government of India during the G20 Health Working Group meeting in Gandhinagar last year


YS Biopharma appoints new Directors
People | February 17, 2024

YS Biopharma appoints new Directors

The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024


Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar
Healthcare | February 13, 2024

Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar

Launches collaborative centre for translational research in head and neck cancer


Growth of Ayush sector is bound to happen: Kotecha
Policy | February 09, 2024

Growth of Ayush sector is bound to happen: Kotecha

Ayush is expanding beyond wellness to therapeutic wellness


Qure.ai adds new FDA breakthrough device status for qSpot-TB
Digitisation | February 09, 2024

Qure.ai adds new FDA breakthrough device status for qSpot-TB

4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months


Mandaviya inaugurates new headquarters of the National Dental Commission
News | February 06, 2024

Mandaviya inaugurates new headquarters of the National Dental Commission

Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges


AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
Clinical Trials | January 31, 2024

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation


Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40
Clinical Trials | January 30, 2024

Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40